Toggle navigation
Works
People
Organizations
Repositories
Pages
About
Statistics
Support
Sign In
Loading...
Loading...
A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-resistant Temporal Lobe Epilepsy - The SeLECT Study
https://doi.org/10.26180/23632326
Loading...
Download Metadata
Cite as
APA
Harvard
MLA
Vancouver
Chicago
IEEE
Download Reports
Related Works (CSV)
Share
Email
Twitter
Facebook
Description
Creators
Registration
Sodium selenate, 15mg three times a day, 26 weeks, oral tablet. Participants will be required to return unused tablets to site each visit to monitor compliance with dosing regimen.
Terence O'Brien
DOI registered
July 6, 2023
via DataCite
Dataset published 2023 in
Monash University
Dataset